Skip to main content

Table 3 WC

From: Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials

Standard + Glp-1

        

−0.35 (−2.56,1.86)

Glp-1

       

−2.09 (−5.87,1.70)

−1.74 (−5.18,1.71)

Flutamide

      

−2.85 (−5.54,−0.16)

−2.50 (−4.75,−0.25)

−0.76 (−4.17,2.65)

Sglt-2

     

−2.31 (−12.30,7.68)

−1.96 (−11.77,7.85)

−0.22 (−10.49,10.04)

0.54 (−9.38,10.45)

Roflumilast

    

−3.74 (−5.98,−1.49)

−3.39 (−4.96,−1.82)

−1.65 (−4.77,1.46)

−0.89 (−2.46,0.67)

−1.43 (−11.24,8.38)

Orlistat

   

−4.39 (−6.75,−2.02)

−4.04 (−5.99,−2.09)

−2.30 (−5.42,0.81)

−1.54 (−3.01,−0.08)

−2.08 (−11.91,7.75)

−0.65 (−1.39,0.09)

Standard

  

−4.88 (−8.46,−1.31)

−4.54−7.75,−1.32)

−2.80 (−6.14,0.54)

−2.04 (−5.21,1.14)

−2.57 (−12.77,7.62)

−1.14 (−4.00,1.71)

−0.50 (−3.35,2.35)

Standard + Flutamide

 

−5.34 (−7.49,−3.19)

−4.99 (−6.17,−3.82)

−3.26 (−6.38,−0.14)

−2.50 (−4.16,−0.83)

−3.03 (−12.82,6.75)

−1.60 (−2.30,−0.90)

−0.95 (−1.99,0.08)

−0.46 (−3.32,2.40)

Placebo